| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-073 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、董事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2024 年 8 月 19 日以电 子邮件方式发出第五届董事会第五次会议通知，会议于 2024 年 8 月 29 日以现场 加通讯方式召开，应参加表决的董事 9 人，实际参加表决的董事 9 人，部分公司 监事和高级管理人员列席了会议，本次会议的召集、召开和表决程序符合有关法 律、法规和《公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 本次会议由董事长高毅先生召集并主持，采用记名投票方式，审议并通过了 如下议案： 1. 《关于 2024 年半年度报告及其摘要的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 797,718,135.20 for the first half of 2024, representing a 13.13% increase compared to RMB 705,153,553.66 in the same period last year[4]. - Total operating revenue for the first half of 2024 was RMB 11,762,401,111.51, up 9.86% from RMB 10,706,563,008.05 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was RMB 785,779,829.12, reflecting a 15.77% increase from RMB 678,767,966.92 in the previous year[15]. - Basic earnings per share for the reporting period (January to June) increased to 0.66 CNY, up 13.79% from 0.58 CNY in the same period last year[18]. - The weighted average return on equity decreased to 7.79%, a decline of 0.16 percentage points compared to 7.95% in the previous year[18]. - The company reported a significant increase in user data, although specific figures were not disclosed in the report[6]. Cash Flow and Assets - The net cash flow from operating activities increased by 29.41% to RMB 1,821,698,317.33, compared to RMB 1,407,732,764.48 in the same period last year[15]. - The company's total assets reached RMB 26,436,820,335.65, a 9.53% increase from RMB 24,136,539,194.64 at the end of the previous year[17]. - The company's financial assets increased by 93.23% to CNY 3,151 million, primarily due to investments in bank wealth management products[60]. - The company's cash and cash equivalents increased to 4,188,079,298.52 CNY as of June 30, 2024, up from 3,565,905,738.81 CNY at the end of 2023, representing a growth of approximately 17.4%[120]. - The total current assets of the company as of June 30, 2024, amounted to 13,934,437,376.85 CNY, compared to 12,128,910,739.25 CNY at the end of 2023, indicating an increase of about 14.9%[120]. Market and Industry Insights - The total retail market size for pharmaceuticals reached 516 billion CNY in 2023, representing a year-on-year growth of 2.89%[26]. - The number of retail pharmacies in China grew by 30,700 to 654,000 in 2023, indicating a steady increase in the industry[26]. - The chain pharmacy market concentration increased, with the top 100 chain companies accounting for 59.50% of total industry sales, up 3.66% from 2022[24]. - The retail pharmacy industry in China is experiencing increasing concentration, with the top 100 companies' sales growth outpacing the overall industry growth[29]. Store Operations and Expansion - As of June 30, 2024, the company operated 14,736 chain pharmacies, including 3,426 franchise stores, with a net increase of 1,486 stores compared to the previous period[40]. - The company opened 1,575 new stores during the reporting period, including 842 self-built stores, 293 acquired stores, and 440 franchise stores[40]. - The company has established modern logistics centers in several provinces, enhancing its supply chain capabilities with advanced equipment and technology[35]. - The company has embraced digital transformation, utilizing CRM and big data to develop an integrated online and offline pharmaceutical retail model since 2013[38]. Research and Development - The company is actively involved in the research and development of traditional Chinese medicine through its subsidiary, Hengxiutang Pharmaceutical Co., Ltd.[22]. - Research and development expenses increased by 71.11% to CNY 16.87 million, compared to CNY 9.86 million in the previous year[59]. - The company reported a significant increase in development expenditure for data resources, rising to ¥22,467,421.51 from ¥3,496,698.64, a growth of approximately 541.5%[121]. Corporate Governance and Compliance - The company has undergone significant changes in its board and management, with multiple resignations and elections, including the appointment of a new Vice President and CFO[76]. - The company has committed to avoiding any competition with its subsidiaries and has made long-term commitments to prevent conflicts of interest[81]. - The company guarantees that it will maintain complete operational independence between itself and Yifeng Pharmacy, adhering to regulations set by the China Securities Regulatory Commission[84]. Financial Management and Strategy - The company has committed to fair pricing principles in all related transactions, ensuring prices are comparable to those from unrelated third parties[93]. - The company reported a total transaction amount of 6,233.39 million RMB in related party transactions during the first half of 2024[93]. - The company has a share lock-up period of 36 months from the date of its stock listing, during which no shares can be transferred or managed by others[88]. - The company has outlined strict compliance with laws regarding short-term trading for any convertible bond issuance[88]. Environmental and Social Responsibility - The company has implemented various carbon reduction measures, including the use of energy-efficient LED lighting and the promotion of new energy vehicles in logistics[80]. - The company has not faced any environmental penalties and adheres to national environmental protection laws and regulations[79]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 21,465[112]. - The top ten shareholders hold a total of 262,492,776 shares, representing 21.65% of the total shares[112]. - The company allocated 288,681,972.00 RMB to shareholders during the reporting period, indicating a focus on returning value to investors[148].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-072 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 转股价格：32.79 元/股 转股期：自发行结束之日（2024 年 3 月 8 日，T+4 日）起满六个月后的第 一个交易日（2024 年 9 月 8 日）起至可转债到期日（2030 年 3 月 3 日）止（如 遇法定节假日或休息日延至其后的第 1 个工作日；顺延期间付息款项不另计息）。 风险提示：自 2024 年 8 月 12 日至 2024 年 8 月 23 日，益丰大药房连锁股份 有限公司（以下简称"公司"、"本公司"）股票已有 10 个交易日的收盘价低 于当期转股价格的 85%，预计触发转股价格向下修正条件。若触发条件，公司将 于触发条件当日召开董事会审议决定是否修正转股价格，并及时履行信息披露义 务。敬请广大投资者注意投资风险。 一、 "益丰转债"发行上市概况 益丰大药房连锁股份有限公司 关于预计触发"益丰转债"转股价格向下修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）召开的第四 届董事会第三十八次会议审议通过了《关于使用部分闲置募集资金暂时补充流 动资金的议案》，同意公司合计使用不超过 128,000.00 万元暂时闲置的募集资 金暂时补充流动资金，用于与主营业务相关的生产经营活动，使用期限自董事 会审议通过之日起不超过 12 个月。具体内容详见 2024 年 4 月 17 日披露在上 海证券交易所网站（www.sse.com.cn）及法定披露媒体的《关于使用部分闲置 募集资金暂时补充流动资金的公告》（公告编号：2024-030）。截至本公告披 露日，公司累计实际使用暂时闲置可转换公司债券募集资金补充流动资金合计 为 126,000.00 万元。 近日，公司归还 1,500.00 万元至募集资金专户，并将上述归还事项及时通 知了保荐机构与保荐代表人。 截至本公告披露日，累计归还 1,500.00 万元至募集资金专户，公司使用可 转换公司债券募集资金补充流动资金余额为 124,500.00 万元。公司将在到期日 之前全部归还至募集资金专用账户，并及时履行相关信息披露义务。 特此公告。 | 证券代码：603939 | ...

Summary of the Conference Call Company and Industry Involved - The conference call is focused on the animal medicine industry, specifically discussing the company "Yifeng Pharmacy" [1] Core Points and Arguments - The presentation is led by a pharmaceutical researcher, Su Feng, who provides insights into the current situation of Yifeng Pharmacy [1] Other Important but Possibly Overlooked Content - The call emphasizes the importance of the animal medicine sector and its growth potential, although specific data and metrics are not provided in the excerpt [1]

Summary of Conference Call Company and Industry - The conference call focused on the animal medicine industry, specifically discussing the company Yifeng Pharmacy [1]. Core Points and Arguments - The research team maintains a positive outlook on leading companies within the animal medicine sector, including Yifeng Pharmacy [1]. Other Important Content - The call emphasized the importance of understanding the dynamics of the animal medicine market and the role of leading enterprises in driving growth [1].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-070 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、 本次委托理财的情况 重要内容提示： 本次赎回产品名称：利多多公司稳 24JG335 期(礼财日 A 款)人民币对公结 构性存款 赎回金额：8,000 万元 本次继续委托理财金额：10,700 万元 已履行的审议程序：经公司第四届董事会第三十八次会议审议通过 特别风险提示：公司将对投资产品进行严格评估，尽管公司选择本金保障 类理财产品，但金融市场受宏观经济的影响较大，不排除该项投资受到市场波动 的影响，面临收益波动风险、流动性风险、信用风险、操作风险、信息技术系统 风险、政策法律风险、不可抗力及意外事件风险、信息传递等风险。 一、 本次赎回理财产品的情况 2024 年 7 月 4 日，公司使用闲置募 ...

目 录 一、以自筹资金预先投入募投项目及支付发行费用的鉴证报告…第 1—2 页 二、以自筹资金预先投入募投项目及支付发行费用的专项说明…第 3—5 页 三、附件 …………………………………………………………… 第 6—9 页 （一）本所营业执照复印件 ………………………………………第 6 页 （二）本所执业证书复印件 ………………………………………第 7 页 （三）本所签字注册会计师执业证书复印件 ………………第 8—9 页 关于益丰大药房连锁股份有限公司 以自筹资金预先投入募投项目及支付发行费用的 鉴证报告 天健审〔2024〕2-98 号 益丰大药房连锁股份有限公司全体股东： 我们鉴证了后附的益丰大药房连锁股份有限公司（以下简称益丰药房公司） 管理层编制的《以自筹资金预先投入募投项目及支付发行费用的专项说明》。 我们按照中国注册会计师执业准则的规定执行了鉴证业务。中国注册会计师 执业准则要求我们计划和实施鉴证工作，以对鉴证对象信息是否不存在重大错报 获取合理保证。在鉴证过程中，我们实施了包括核查会计记录等我们认为必要的 程序。我们相信，我们的鉴证工作为发表意见提供了合理的基础。 一、对报告使用者和使用目的的 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-069 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用募集资金置换预先投入募投项目及已支付 | 项目名称 | 总投资额 | 募集资金 | 项目备案 | | --- | --- | --- | --- | | | | 投资额 | 或核准文号 | | 江苏二期、湖北医 | 43,900.23 | 43,202.15 | 江苏省投资项目备案证（宁经管委行审备 | | | | | 〔2022〕278 号）、湖北省固定资产投资 | | 药分拣加工中心及 | | | 项 目 备 案 证 （ 登 记 备 案 项 目 代 码 ： | | 河北医药库房建设 | | | 2019-420114-51-03025970）、河北企业投 | | 项目 | | | 资项目备案信息（备案编号：鹿开投资备 | | | | | 字〔2022〕114 号） | | 益丰数字化平台升 | 8,064.20 | 8,064.20 | 常德市武陵区发展和改革局备案证明（备 | | 级 ...

中信证券股份有限公司 关于益丰大药房连锁股份有限公司使用募集资金置换 预先投入募投项目及已支付发行费用的自筹资金的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为益丰大 药房连锁股份有限公司（以下简称"益丰药房"、"公司"）向不特定对象发行 可转换公司债券的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》和《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》等规定，对益丰药房拟使用募集资金置换预先投入募投项目 及已支付发行费用的自筹资金事项进行了核查，并出具核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意益丰大药房连锁股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕109 号），公司 由主承销商中信证券采用余额包销方式，向社会公众公开发行可转换公司债券 1,797.4320 万张，每张面值为人民币 100.00 元，按面值发行，共计募集资金 179,743.20 万元，坐扣承销和保荐费用 1,350.00 万元(含税）后的募集资金为 178,393.20 万元，已由主承销商中信证券于 ...